Stéphane Marot
A5036956171- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- SARS-CoV-2 detection and testing
- Respiratory viral infections research
- COVID-19 and healthcare impacts
- Bacillus and Francisella bacterial research
- Herpesvirus Infections and Treatments
- Poxvirus research and outbreaks
- Viral Infections and Immunology Research
- Mosquito-borne diseases and control
- Kawasaki Disease and Coronary Complications
- Viral Infections and Vectors
- Vaccine Coverage and Hesitancy
- Viral gastroenteritis research and epidemiology
- Immunotherapy and Immune Responses
- Advanced biosensing and bioanalysis techniques
- Blood Coagulation and Thrombosis Mechanisms
- Immunodeficiency and Autoimmune Disorders
- Parvovirus B19 Infection Studies
- Mycobacterium research and diagnosis
- Heparin-Induced Thrombocytopenia and Thrombosis
- Animal Virus Infections Studies
- Cardiac Structural Anomalies and Repair
- Biosensors and Analytical Detection
Inserm
2020-2025
Sorbonne Université
2020-2025
Institut Pierre Louis d‘Épidémiologie et de Santé Publique
2020-2025
Assistance Publique – Hôpitaux de Paris
2018-2025
Pitié-Salpêtrière Hospital
2020-2025
National Center for Emerging and Zoonotic Infectious Diseases
2025
Centers for Disease Control and Prevention
2025
Department of Virology
2022-2024
Hôpital Avicenne
2016-2024
Hôpital Charles-Foix
2023
There are only few data concerning persistence of neutralizing antibodies (NAbs) among SARS-CoV-2-infected healthcare workers (HCW). These individuals particularly exposed to SARS-CoV-2 infection and at potential risk reinfection. We followed 26 HCW with mild COVID-19 three weeks (D21), two months (M2) (M3) after the onset symptoms. All had anti-receptor binding domain (RBD) IgA D21, decreasing 38.5% M3 (p < 0.0001). Concomitantly a significant decrease in NAb titers was observed between D21...
At the end of 2021, B.1.1.529 SARS-CoV-2 variant (Omicron) wave superseded B.1.617.2 (Delta) wave.To compare baseline characteristics and in-hospital outcomes patients with infection Delta versus Omicron in emergency department (ED).Retrospective chart reviews.13 adult EDs academic hospitals Paris area from 29 November 2021 to 10 January 2022.Patients a positive reverse transcriptase polymerase chain reaction (RT-PCR) test result for identification.Main outcome measures were clinical...
A low anti-spike antibody response of 28.6% was observed 28 days after BNT162b2 vaccine second dose among 133 solid organ transplant recipients without previous coronavirus disease 2019 (COVID-19). No serious adverse events were recorded. Four severe COVID-19 cases reported between or the 2 doses. Our data suggest to change strategy.
Abstract Infection with SARS-CoV-2 variant Omicron is considered to be less severe than infection Delta, rarer occurrence of disease requiring intensive care. Little information available on comorbid factors, clinical conditions and specific viral mutational patterns associated the severity infection. In this multicenter prospective cohort study, patients consecutively admitted for COVID-19 in 20 care units France between December 7th 2021 May 1st 2022 were included. Among 259 patients, we...
Abstract We have assessed antiviral activity and induction of protective immunity fusion-inhibitory lipopeptides derived from the C-terminal heptad-repeat domain SARS-CoV-2 spike glycoprotein in transgenic mice expressing human ACE2 (K18-hACE2). The block infection cell lines lung-derived organotypic cultures. Intranasal administration allows maintenance homeostatic transcriptomic immune profile lungs, prevents body-weight loss, decreases viral load shedding, protects death caused by...
We explored the molecular evolution of spike gene after administration anti-spike monoclonal antibodies in patients with mild or moderate forms COVID-19. Four out 13 acquired a mutation during follow-up; two mutations (G1204E and E406G) appeared as mixture without clinical impact, while Q493R emerged (one receiving bamlanivimab one bamlanivimab/etesevimab) fatal outcomes. Careful virological monitoring treated mAbs should be performed, especially immunosuppressed patients.
Previous reports have shown a variability in the diagnostic performance of RDTs. In era SARS-CoV-2 variants and use RDT, mutation associated with these could affect test performance.